EA202092291A1 - Соединение на основе хинолина или хиназолина и его применение - Google Patents
Соединение на основе хинолина или хиназолина и его применениеInfo
- Publication number
- EA202092291A1 EA202092291A1 EA202092291A EA202092291A EA202092291A1 EA 202092291 A1 EA202092291 A1 EA 202092291A1 EA 202092291 A EA202092291 A EA 202092291A EA 202092291 A EA202092291 A EA 202092291A EA 202092291 A1 EA202092291 A1 EA 202092291A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- quinoline
- quinazoline
- present
- compound
- application
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 title abstract 5
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title abstract 3
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 230000005917 in vivo anti-tumor Effects 0.000 abstract 1
- 230000009545 invasion Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
Настоящее изобретение относится к соединению на основе хинолина или хиназолина, представленному формулой (I), его фармацевтически приемлемой соли, его стереоизомеру, молекуле пролекарства на его основе или дейтерированному соединению на его основе. Соединение по настоящему изобретению является эффективным в подавлении действия протеинкиназы AXL и может подавлять пролиферацию, миграцию и инвазию различных опухолевых клеток. Дополнительно соединение на основе хинолина или хиназолина по настоящему изобретению имеет отличную метаболическую стабильность, высокую противоопухолевую активность in vivo, слабые токсичные побочные эффекты, и его можно использовать для получения лекарственного средства для предупреждения гиперпролиферативных заболеваний, таких как опухоли, у людей и других млекопитающих.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810277244 | 2018-03-30 | ||
PCT/CN2019/080659 WO2019185064A1 (zh) | 2018-03-30 | 2019-03-29 | 喹啉或喹唑啉类化合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202092291A1 true EA202092291A1 (ru) | 2021-01-20 |
Family
ID=68062547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202092291A EA202092291A1 (ru) | 2018-03-30 | 2019-03-29 | Соединение на основе хинолина или хиназолина и его применение |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210078972A1 (ru) |
EP (1) | EP3778585B1 (ru) |
JP (1) | JP7036332B2 (ru) |
KR (1) | KR102577460B1 (ru) |
CN (1) | CN112351971B (ru) |
AU (1) | AU2019241374B2 (ru) |
CA (1) | CA3095946C (ru) |
DK (1) | DK3778585T3 (ru) |
EA (1) | EA202092291A1 (ru) |
ES (1) | ES2936263T3 (ru) |
IL (1) | IL277671B2 (ru) |
PT (1) | PT3778585T (ru) |
SG (1) | SG11202009328TA (ru) |
WO (1) | WO2019185064A1 (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113278010A (zh) * | 2021-06-01 | 2021-08-20 | 中国科学院上海有机化学研究所 | 一类蛋白激酶降解剂及其用途 |
CN113480418B (zh) * | 2021-07-13 | 2022-09-06 | 上海健康医学院 | 一种化合物,及其在制备治疗癌症药物方面的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5525612B2 (ja) * | 2010-07-23 | 2014-06-18 | 国立大学法人 東京大学 | 含窒素複素環誘導体 |
CN102643268B (zh) * | 2011-12-30 | 2014-05-21 | 沈阳药科大学 | 喹啉类及噌啉类化合物及其应用 |
CN106467541B (zh) * | 2015-08-18 | 2019-04-05 | 暨南大学 | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 |
CN107151240A (zh) * | 2016-03-04 | 2017-09-12 | 中国科学院上海药物研究所 | 一类多取代喹诺酮类化合物及其制备方法和用途 |
CN110264326B (zh) * | 2019-05-24 | 2023-03-24 | 创新先进技术有限公司 | 识别异常账户集合和风险账户集合的方法、装置及设备 |
CN110715124A (zh) * | 2019-11-18 | 2020-01-21 | 好暖科技(深圳)有限公司 | 一种螺旋管接口防漏水结构、螺旋管冲压平波器及方法 |
-
2019
- 2019-03-23 IL IL277671A patent/IL277671B2/en unknown
- 2019-03-29 EP EP19777026.6A patent/EP3778585B1/en active Active
- 2019-03-29 PT PT197770266T patent/PT3778585T/pt unknown
- 2019-03-29 US US17/044,322 patent/US20210078972A1/en active Pending
- 2019-03-29 ES ES19777026T patent/ES2936263T3/es active Active
- 2019-03-29 WO PCT/CN2019/080659 patent/WO2019185064A1/zh unknown
- 2019-03-29 CN CN201980022849.XA patent/CN112351971B/zh active Active
- 2019-03-29 EA EA202092291A patent/EA202092291A1/ru unknown
- 2019-03-29 SG SG11202009328TA patent/SG11202009328TA/en unknown
- 2019-03-29 AU AU2019241374A patent/AU2019241374B2/en active Active
- 2019-03-29 JP JP2021501073A patent/JP7036332B2/ja active Active
- 2019-03-29 DK DK19777026.6T patent/DK3778585T3/da active
- 2019-03-29 KR KR1020207031331A patent/KR102577460B1/ko active IP Right Grant
- 2019-03-29 CA CA3095946A patent/CA3095946C/en active Active
Also Published As
Publication number | Publication date |
---|---|
IL277671B2 (en) | 2024-03-01 |
WO2019185064A1 (zh) | 2019-10-03 |
PT3778585T (pt) | 2023-01-20 |
CA3095946A1 (en) | 2019-10-03 |
ES2936263T3 (es) | 2023-03-15 |
CA3095946C (en) | 2023-04-25 |
IL277671A (en) | 2020-11-30 |
EP3778585A1 (en) | 2021-02-17 |
DK3778585T3 (da) | 2022-12-19 |
AU2019241374B2 (en) | 2021-08-19 |
AU2019241374A1 (en) | 2020-11-26 |
JP2021519345A (ja) | 2021-08-10 |
CN112351971A (zh) | 2021-02-09 |
SG11202009328TA (en) | 2020-10-29 |
KR102577460B1 (ko) | 2023-09-12 |
CN112351971B (zh) | 2022-11-22 |
EP3778585A4 (en) | 2021-02-17 |
JP7036332B2 (ja) | 2022-03-15 |
KR20210005036A (ko) | 2021-01-13 |
US20210078972A1 (en) | 2021-03-18 |
EP3778585B1 (en) | 2022-10-19 |
IL277671B1 (en) | 2023-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123756T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
MX2020013373A (es) | Compuestos de naftiridinona utiles como activadores de celulas t. | |
EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
EA201790088A1 (ru) | Ингибиторы syk | |
WO2018155916A3 (ko) | 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 | |
PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
EA201690752A1 (ru) | Ингибиторы g12c kras | |
EA201591745A1 (ru) | 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh | |
WO2016164675A8 (en) | Substituted quinazoline compounds and methods of use thereof | |
EA201591906A1 (ru) | Производные мочевины, полезные в качестве ингибиторов киназы | |
EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
EA201791727A1 (ru) | 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-а]пиридо[3,4-е]пиримидин-5(1н)-он, его аналоги и соли и способы их применения в терапии | |
EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
EA201490696A1 (ru) | 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантной idh | |
EA201270373A1 (ru) | Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли | |
EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
EA201591327A1 (ru) | Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений | |
EA201690386A1 (ru) | Соединения и композиции в качестве ингибиторов mek | |
MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
EA202192905A1 (ru) | Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли | |
MX2021006619A (es) | Inhibidores de la tirosina quinasa, composiciones y sus metodos. |